

Evonik offers substitutes for polyamide 12

April 26, 2012

Three weeks after the fire in the CDT plant in the Marl Chemical Park, Evonik Industries is offering its customers various substitutes for polyamide 12 (PA 12), which will be available only in smaller volumes during plant repairs: The extrusion and injection molding compounds based on PA 610, PA 612, PA 1010, and PA 1012 do not require CDT as precursor. They are particularly suitable for use in line systems in the automotive supply industry, including the multi-layer tubing systems patented by Evonik. One such substitute is the bio-based VESTAMID® *Terra*, already being used by the automotive industry.

Oliver Luckenbach
Head of Investor Relations
Phone +49 201 177-3145
Fax +49 201 177-3148
oliver.luckenbach@evonik.com

The materials offered feature technical properties that are comparable with those of PA 12 and have similar processability. Evonik actively stands by its customers to support them in the best way possible in the selection and qualification process of the alternative materials and in minimizing the impact on supply chains.

Substitutes for VESTOSINT® PA 12 powder will also become available within the next few weeks. This product is used in household appliances, paints and coatings, and cosmetics.

In the present state of knowledge, the CDT plant is expected to be operational again in the fourth quarter of 2012. The regulatory authorities are still investigating the cause of the accident.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary,

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Supervisory Board
Wilhelm Bonse-Geuking, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Dr. Wolfgang Colberg,
Dr. Thomas Haeberle,
Thomas Wessel,
Patrik Wohlhauser, Dr. Dahai Yu

Registered office Essen
Register Court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.